With [3H]Mepyramine (Trieyclic Antidepressants/Antihistamine/Neurotransmitter/Amitriptyline) VINH TAN TRAN, RAYMOND S

Total Page:16

File Type:pdf, Size:1020Kb

With [3H]Mepyramine (Trieyclic Antidepressants/Antihistamine/Neurotransmitter/Amitriptyline) VINH TAN TRAN, RAYMOND S Proc. Nati. Acad. Sci. USA Vol. 75, No. 12, pp. 6290-6294,, December 1978 Neurobiology Histamine H1 receptors identified in mammalian brain membranes with [3H]mepyramine (trieyclic antidepressants/antihistamine/neurotransmitter/amitriptyline) VINH TAN TRAN, RAYMOND S. L. CHANG, AND SOLOMON H. SNYDER* Departments of Pharmacology and Experimental Therapeutics, and Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205 Communicated by Julius Axelrod, August 30,1978 ABSTRACT The antihistamine [3H mepyramine binds to Male Sprague-Dawley rats (150-200 g) were killed by cer- HI histamine receptors in mammalian brain membranes. vical dislocation, their brains were rapidly removed and ho- Potencies of H1 antihistamines at the binding sites correlate mogenized with a Polytron for 30 min (setting 5) in 30 vol of with their pharmacological antihistamine effects in the guinea pig ileum. Specific [3Himepyramine binding is saturable with ice-cold Na/K phosphate buffer (50 mM, pH 7.5), and the a dissociation constant of about 4 nM in both equilibrium and suspension was centrifuged (50,000 X g for 10 min). The pellet kinetic experiments and a density of 10pmolper gram ofwhole was resuspended in the same volume of fresh buffer and cen- brain. Some tricyclic antidepressants are potent inhibitors of trifuged, and the final pellet was resuspended in the original secific [3Hmepamine binding. Regional variations of volume of ice-cold buffer by Polytron homogenization. Calf [3Hjmepyramine ing do not correlate with variations in brains were obtained from a local abattoir within 2 hr after the endogeneous histamine and histidine decarboxylase activity. death of the animals and transferred to the laboratory in ice- Histamine is a neurotransmitter candidate in mammalian brain cold saline. The brain was quickly dissected into individual (1-3). Effects of histamine on cyclic AMP and cyclic GMP regions on ice and stored frozen in plastic vials at -70'C until formation may reflect H2 and HI receptor influences, respec- use. Male Hartley guinea pigs (300-400 g) were used. tively (4-8). Preliminary reports described the labeling of his- To measure specific binding of [3H]mepyramine, [f3H]- tamine HI receptors in rat brain (9) and guinea pig ileum (10) mepyramine and unlabeled substances were added to 0.45 ml with [3H]mepyramine. We now present detailed properties of of tissue homogenate with a final incubation volume of 0.5 ml. labeled with Incuation was carried out at 250C for 20-30 min and termi- histamine HI receptors in mammalian brain nated by addition of 4 ml of ice-cold buffer followed by rapid [3H]mepyramine. filtration onto glass fiber filters (GF/B) positioned over a vac- MATERIALS AND METHODS uum and subsequently with three 4-ml washes of cold buffer. Radioactivity trapped on the filters was counted in 10 ml of [3H]Mepyramine (30 Ci/mmol) was prepared by tritium re- Aquasol (New England Nuclear) at an efficiency of 38% after duction of dibrominated mepyramine at New England Nu- a 12-hr stoarge at 4VC. Specific binding was defined as radio- clear. The tritiated material migrated as a single band in thin activity bound after subtraction of nonspecific binding deter- layer chromatography on silica gel and cellulose in 1- mined in the presence of 2MiM triprolidine. Maximal reduction butanol/glacial acetic acid/water, 2:4:1 (vol/vol). a-Chymo- of binding by triprolidine to 40% of total binding levels is trypsin (EC 3.4.21.1; 60 units/mg), phospholipase C (EC 3.1.4.3; constant over the range 0.1-10 MM. Thin layer chromatography from Clostridlum perfringens, 70 units/mg proteirn), and of membranes and medium showed no metabolism of [3H]- trypsin (EC 3.4.21.4; 195 units/mg) were obtained from mepyramine. Worthington. Phospholipase A (EC 3.1.1.4; from bee venom, 1230 units/mg protein), was purchased from Sigma. Com- RESULTS pounds were obtained from the following sources: pyrathiazine Specific [3H]mepyramine binding, total minus nonspecific (Upjohn); promethazine (Wyeth Laboratories, Philadelphia, binding, is linear with tissue concentrations in the range 2-20 PA); trimeprazine, diphenylpyraline, chlorpromazine, meti- mg of wet weight and displays a sharp pH optimum at 7.5. amide, cimetidine, trifluoperazine (Smith, Kline and French Specific [3H]mepyramine binding becomes saturated with Laboratories); methdilazine (Mead Johnson, Evansville, IN); increasing concentrations (Fig. 1). With 0.3 nM receptor con- methapyraline, nortriptyline (Eli Lilly); mepyramine (Robinson centration, which is 10% of the dissociation constant (Kd) (11), Laboratory, San Francisco, CA); chlorcyclizine, triprolidine Scatchard analysis reveals a single population of binding sites (Burroughs Wellcome, Research Triangle Park, NC); antistine, with a Kd of 4.5 nM and a maximal number of binding sites tripelennamine, dimethindene (CIBA, Summit, NJ); meclizine, Bmax of 10.7 pmol per gram of tissue (Fig. 1 middle), re- doxepin (Pfizer); carbinoxamine (McNeil Laboratory, Fort sembling densities of muscarinic, cholinergic, opiate, and a- Washington, PA); phenindamine (Hoffman-LaRoche); or- and fl-adrenergic receptors (12). Hill plots are linear with a Hill phenadrine (Riker Laboratories, Northridge, CA); brom- coefficient of 1.01 (Fig. 1 bottom). pheniramine (Robins Research Laboratory, Richmond, VA); Kinetics of Specific [3HlMepyramine Binding. Specific d- and l-chlorpheniramine (Schering, Bloomfield, NJ); flu- [3H]mepyramine binding associates at 250C with a bimolecular phenazine, triflupromazine (Squibb); methysergide (Sandoz, association rate constant (k1) of 0.073 nM-1 min1 (Fig. 2 Hanover, NJ); 1,4-methylhistamine, N-acetylhistamine (Cal- upper). The dissociation of bound [3H]mepyramine at 250C biochem). Dimaprit and 4-methylhismin were generous gifts on a semilog scale is linear with a half-life of about 2.8 min (Fig. from Marshall Plaut, Johns Hopkins University. 2 lower) and a dissociation rate constant (k-1) of 0.26 min-1. The Kd estimated from the ratio (k-1/ki) is 3.6 nM, closely The publication costs of this article were defrayed in part by page similar to the equilibrium Kd. charge payment. This article must therefore be hereby marked "ad- vertisement" in accordance with 18 U. S. C. §1734 solely to indicate this fact. * To whom correspondence should be addressed. 6290 Downloaded by guest on October 2, 2021 Neurobiology: Tran et al. Proc. Natl. Acad. Scz. USA 75(1978) 6291 (A .4-0) -. 0) o 0 D - E a c 30 *11 0. *0c .0 >0 av Ec .0 I v 0 E 0 -. co a a 10 30 IL Time, min V.6 C 70 0 .0 C 7 D 50 ,> ,5 2 E -E 301 a a, -a aU0 ID C 201 0 c- C1 . 10, - \.~~~ 4-E 0 4 6 8 0 Time, min I I FIG. 2. Kinetics of [3H]mepyramine specific binding. (Upper) I Association. Specific [3Hlmepyramine binding to rat brain mem- branes (15 mg of wet weight) at 250C was measured at various time 0 4 8 intervals after the addition of [3H]mepyramine (2 nM). Specific [3H]Mepyramine bound, binding was defined as the difference between the absence and pmol/g of tissue presence of triprolidine (2 ,M). Points shown are those from a single experiment performed in triplicate which was replicated twice. The bimolecular rate constant is calculated according to the equation k 1 = [2.203/t(a - b)]/log [b(a - x)Ia(b - x)], where a is the initial con- centration of 3H-mepyramine (2.0 nM) and b is the initial receptor concentration (0.3 nM). *, Specific binding; 0, nonspecific binding. (Lower) Dissociation. Specifically bound [3H]mepyramine was as- sayed at 250C at various intervals after incubation with [3H]mepy- ramine to equilibrium under standard assay conditions. At time zero, x triprolidine was added to the incubation mixture at a final concen- E tration of 2 gM, and the reaction was terminated by filtration at various intervals. Points shown are those from a single experiment, performed in triplicate, which was replicated twice. C values of 2-3 nM, about 5-8 times more potent than bromodi- phenhydramine and diphenhydramine. Among the ethyl- 0 enediamines, mepyramine, methapyrilene, and triprolidine In[3Hlmepyramine conc. all have Ki values of about 5 nM, whereas antazoline is only 1% FIG. 1. Specific [3H]mepyramine binding to rat brain mem- as potent. d-Chlorpheniramine is about 100 times more potent branes. (Top) Membrane preparations (10-15 mg) were incubated that its I isomer indicating stereospecificity. The H2 antihisti- with various concentrations of [3H]mepyramine at 250C for 20 min mines, burimimide and metiamide, are extremely weak com- in 0.5 ml of 50 mM Na/K phosphate buffer (pH 7.5) in the presence petitors for [3H]mepyramine binding. or absence of 2MuM triprolidine. The experiment was replicated three Histamine itself, with a Ki of 40 ,gM, is substantially weaker times. 0, Total; *, specific; X, nonspecific. (Middle) Scatchard than the H1 antihistamines. However, its effects are selective, analysis of data shown in Top. Kd = 4.5 nM and Bmax = 10.7 pmol/g of tissue. (Bottom) Hill plot of the same data. Slope = 1.01. because 1,4-methylhistamine, virtually inactive at H1 receptors in smooth muscle, is much weaker in competing for [3H]- H1 antihistamines are potent competitors for the specific mepyramine binding. Moreover, dimaprit, 4-methylhistamine, binding of [3H]mepyramine Table 1, Fig. 3). The phenothiazine and 2-aminoethylpyridine, selective H2 receptor agonists, are antihistamines, pyrathiazine and trimeprazine, are most potent substantially weaker than histamine itself. with K, values of about 1 nM, 10-100 times more potent in re- The most potent inhibitors of binding are certain tricyclic ducing [3HJmepyramine binding than are antipsychotic phe- antidepressants. Doxepin (Ki = 0.7 nM) is more potent than any nothiazines. Among the ethanolamine antihistamines, carbi- of the H1 antihistamines evaluated. Amitriptyline (Ki = 4 nM) noxamine and diphenylpyraline are the most potent with K, is comparable in potency to the most active HI antihistamines, Downloaded by guest on October 2, 2021 6292 Neurobiology: Tran et al.
Recommended publications
  • Neurotransmitter Resource Guide
    NEUROTRANSMITTER RESOURCE GUIDE Science + Insight doctorsdata.com Doctor’s Data, Inc. Neurotransmitter RESOURCE GUIDE Table of Contents Sample Report Sample Report ........................................................................................................................................................................... 1 Analyte Considerations Phenylethylamine (B-phenylethylamine or PEA) ................................................................................................. 1 Tyrosine .......................................................................................................................................................................................... 3 Tyramine ........................................................................................................................................................................................4 Dopamine .....................................................................................................................................................................................6 3, 4-Dihydroxyphenylacetic Acid (DOPAC) ............................................................................................................... 7 3-Methoxytyramine (3-MT) ............................................................................................................................................... 9 Norepinephrine ........................................................................................................................................................................
    [Show full text]
  • Medicines Regulations 1984 (SR 1984/143)
    Reprint as at 1 July 2014 Medicines Regulations 1984 (SR 1984/143) David Beattie, Governor-General Order in Council At the Government House at Wellington this 5th day of June 1984 Present: His Excellency the Governor-General in Council Pursuant to section 105 of the Medicines Act 1981, and, in the case of Part 3 of the regulations, to section 62 of that Act, His Excellency the Governor-General, acting on the advice of the Minister of Health tendered after consultation with the organisations and bodies that ap- peared to the Minister to be representatives of persons likely to be substantially affected, and by and with the advice and consent of the Executive Council, hereby makes the following regulations. Contents Page 1 Title and commencement 5 Note Changes authorised by subpart 2 of Part 2 of the Legislation Act 2012 have been made in this official reprint. Note 4 at the end of this reprint provides a list of the amendments incorporated. These regulations are administered by the Ministry of Health. 1 Reprinted as at Medicines Regulations 1984 1 July 2014 2 Interpretation 5 Part 1 Classification of medicines 3 Classification of medicines 11 Part 2 Standards 4 Standards for medicines, related products, medical 11 devices, cosmetics, and surgical dressings 5 Pharmacist may dilute medicine in particular case 12 6 Colouring substances [Revoked] 12 Part 3 Advertisements 7 Advertisements not to claim official approval 13 8 Advertisements for medicines 13 9 Advertisements for related products 15 10 Advertisements for medical devices 15 11 Advertisements
    [Show full text]
  • Histidine Decarboxylase Knockout Mice Production and Signal
    Nitric Oxide Mediates T Cell Cytokine Production and Signal Transduction in Histidine Decarboxylase Knockout Mice This information is current as Agnes Koncz, Maria Pasztoi, Mercedesz Mazan, Ferenc of October 1, 2021. Fazakas, Edit Buzas, Andras Falus and Gyorgy Nagy J Immunol 2007; 179:6613-6619; ; doi: 10.4049/jimmunol.179.10.6613 http://www.jimmunol.org/content/179/10/6613 Downloaded from References This article cites 41 articles, 8 of which you can access for free at: http://www.jimmunol.org/content/179/10/6613.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average by guest on October 1, 2021 Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2007 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Nitric Oxide Mediates T Cell Cytokine Production and Signal Transduction in Histidine Decarboxylase Knockout Mice1 Agnes Koncz,*† Maria Pasztoi,* Mercedesz Mazan,* Ferenc Fazakas,‡ Edit Buzas,* Andras Falus,*§ and Gyorgy Nagy2,3*¶ Histamine is a key regulator of the immune system.
    [Show full text]
  • Glucocorticoids with Ketamine and Pentobarbitone- Induced General Anaesthesia in the Rat: Possible Effects on Central Cholinergic Activity
    Br. J. Pharmac. (1984), 82,339-347 Interactions of cholinesterase inhibitors and glucocorticoids with ketamine and pentobarbitone- induced general anaesthesia in the rat: possible effects on central cholinergic activity Remy S. Leeuwin, Jan K. van der Wal & Willem Spanjer Pharmacological Laboratory, University of Amsterdam, Polderweg 104,1093 KP Amsterdam, The Netherlands 1 Doses of 100, 150 and 200 igkg-1 of the cholinesterase inhibitor neostigmine reverse the anaesthetic action of ketamine. The antagonistic effect is increased as the dose is increased. The duration of anaesthesia induced by pentobarbitone is reversed by the cholinesterase inhibitor in doses of 150, 200 and 250 tig kg-1. 2 Choline, in a dose of 50mg kg-, significantly antagonizes the action of the two anaesthetics, whereas hemicholinium-3, an inhibitor of the uptake of choline and the synthesis of acetylcholine, markedly potentiates their action. 3 Dexamethasone induces a significant reduction of the duration of anaesthesia produced by ketamine and pentobarbitone. The potentiation of the anaesthetic effect caused by hemicholinium-3 is also reversed by dexamethasone. 4 The acetylcholine content in rat cerebral cortex is increased after treatment with ketamine and pentobarbitone. 5 Measurements of the course of the plasma level of pentobarbitone do not reveal alterations in the pharmacokinetic profile by either neostigmine or dexamethasone. 6 These results indicate that central cholinergic systems may somehow be involved in the anaesthesia induced by ketamine and pentobarbitone and that the interactions described in this paper may be the result of modification by neostigmine and dexamethasone of the alterations in cholinergic activity caused by the two anaesthetics. Introduction In 1977 Balmer & Wyte showed that physostigmine after completion of the operation was actually pro- antagonized the sedative effects of diazepam and longed.
    [Show full text]
  • Pharmacology and Toxicology of Amphetamine and Related Designer Drugs
    Pharmacology and Toxicology of Amphetamine and Related Designer Drugs U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol Drug Abuse and Mental Health Administration Pharmacology and Toxicology of Amphetamine and Related Designer Drugs Editors: Khursheed Asghar, Ph.D. Division of Preclinical Research National Institute on Drug Abuse Errol De Souza, Ph.D. Addiction Research Center National Institute on Drug Abuse NIDA Research Monograph 94 1989 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse 5600 Fishers Lane Rockville, MD 20857 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, DC 20402 Pharmacology and Toxicology of Amphetamine and Related Designer Drugs ACKNOWLEDGMENT This monograph is based upon papers and discussion from a technical review on pharmacology and toxicology of amphetamine and related designer drugs that took place on August 2 through 4, 1988, in Bethesda, MD. The review meeting was sponsored by the Biomedical Branch, Division of Preclinical Research, and the Addiction Research Center, National Institute on Drug Abuse. COPYRIGHT STATUS The National Institute on Drug Abuse has obtained permission from the copyright holders to reproduce certain previously published material as noted in the text. Further reproduction of this copyrighted material is permitted only as part of a reprinting of the entire publication or chapter. For any other use, the copyright holder’s permission is required. All other matieral in this volume except quoted passages from copyrighted sources is in the public domain and may be used or reproduced without permission from the Institute or the authors.
    [Show full text]
  • 4 Supplementary File
    Supplemental Material for High-throughput screening discovers anti-fibrotic properties of Haloperidol by hindering myofibroblast activation Michael Rehman1, Simone Vodret1, Luca Braga2, Corrado Guarnaccia3, Fulvio Celsi4, Giulia Rossetti5, Valentina Martinelli2, Tiziana Battini1, Carlin Long2, Kristina Vukusic1, Tea Kocijan1, Chiara Collesi2,6, Nadja Ring1, Natasa Skoko3, Mauro Giacca2,6, Giannino Del Sal7,8, Marco Confalonieri6, Marcello Raspa9, Alessandro Marcello10, Michael P. Myers11, Sergio Crovella3, Paolo Carloni5, Serena Zacchigna1,6 1Cardiovascular Biology, 2Molecular Medicine, 3Biotechnology Development, 10Molecular Virology, and 11Protein Networks Laboratories, International Centre for Genetic Engineering and Biotechnology (ICGEB), Padriciano, 34149, Trieste, Italy 4Institute for Maternal and Child Health, IRCCS "Burlo Garofolo", Trieste, Italy 5Computational Biomedicine Section, Institute of Advanced Simulation IAS-5 and Institute of Neuroscience and Medicine INM-9, Forschungszentrum Jülich GmbH, 52425, Jülich, Germany 6Department of Medical, Surgical and Health Sciences, University of Trieste, 34149 Trieste, Italy 7National Laboratory CIB, Area Science Park Padriciano, Trieste, 34149, Italy 8Department of Life Sciences, University of Trieste, Trieste, 34127, Italy 9Consiglio Nazionale delle Ricerche (IBCN), CNR-Campus International Development (EMMA- INFRAFRONTIER-IMPC), Rome, Italy This PDF file includes: Supplementary Methods Supplementary References Supplementary Figures with legends 1 – 18 Supplementary Tables with legends 1 – 5 Supplementary Movie legends 1, 2 Supplementary Methods Cell culture Primary murine fibroblasts were isolated from skin, lung, kidney and hearts of adult CD1, C57BL/6 or aSMA-RFP/COLL-EGFP mice (1) by mechanical and enzymatic tissue digestion. Briefly, tissue was chopped in small chunks that were digested using a mixture of enzymes (Miltenyi Biotec, 130- 098-305) for 1 hour at 37°C with mechanical dissociation followed by filtration through a 70 µm cell strainer and centrifugation.
    [Show full text]
  • In Vitro Pharmacology of Clinically Used Central Nervous System-Active Drugs As Inverse H1 Receptor Agonists
    0022-3565/07/3221-172–179$20.00 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS Vol. 322, No. 1 Copyright © 2007 by The American Society for Pharmacology and Experimental Therapeutics 118869/3215703 JPET 322:172–179, 2007 Printed in U.S.A. In Vitro Pharmacology of Clinically Used Central Nervous System-Active Drugs as Inverse H1 Receptor Agonists R. A. Bakker,1 M. W. Nicholas,2 T. T. Smith, E. S. Burstein, U. Hacksell, H. Timmerman, R. Leurs, M. R. Brann, and D. M. Weiner Department of Medicinal Chemistry, Leiden/Amsterdam Center for Drug Research, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands (R.A.B., H.T., R.L.); ACADIA Pharmaceuticals Inc., San Diego, California (R.A.B., M.W.N., T.T.S., E.S.B., U.H., M.R.B., D.M.W.); and Departments of Pharmacology (M.R.B.), Neurosciences (D.M.W.), and Psychiatry (D.M.W.), University of California, San Diego, California Received January 2, 2007; accepted March 30, 2007 Downloaded from ABSTRACT The human histamine H1 receptor (H1R) is a prototypical G on this screen, we have reported on the identification of 8R- protein-coupled receptor and an important, well characterized lisuride as a potent stereospecific partial H1R agonist (Mol target for the development of antagonists to treat allergic con- Pharmacol 65:538–549, 2004). In contrast, herein we report on jpet.aspetjournals.org ditions. Many neuropsychiatric drugs are also known to po- a large number of varied clinical and chemical classes of drugs tently antagonize this receptor, underlying aspects of their side that are active in the central nervous system that display potent effect profiles.
    [Show full text]
  • Involvement of Sigma-1 Receptors in the Antidepressant-Like Effects of Dextromethorphan
    Involvement of Sigma-1 Receptors in the Antidepressant-like Effects of Dextromethorphan Linda Nguyen, Matthew J. Robson¤, Jason R. Healy, Anna L. Scandinaro, Rae R. Matsumoto* Department of Basic Pharmaceutical Sciences, and Department of Behavioral Medicine and Psychiatry, West Virginia University, Morgantown, West Virginia, United States of America Abstract Dextromethorphan is an antitussive with a high margin of safety that has been hypothesized to display rapid-acting antidepressant activity based on pharmacodynamic similarities to the N-methyl-D-aspartate (NMDA) receptor antagonist ketamine. In addition to binding to NMDA receptors, dextromethorphan binds to sigma-1 (s1) receptors, which are believed to be protein targets for a potential new class of antidepressant medications. The purpose of this study was to determine whether dextromethorphan elicits antidepressant-like effects and the involvement of s1 receptors in mediating its antidepressant-like actions. The antidepressant-like effects of dextromethorphan were assessed in male, Swiss Webster mice using the forced swim test. Next, s1 receptor antagonists (BD1063 and BD1047) were evaluated in conjunction with dextromethorphan to determine the involvement of s receptors in its antidepressant-like effects. Quinidine, a cytochrome P450 (CYP) 2D6 inhibitor, was also evaluated in conjunction with dextromethorphan to increase the bioavailability of dextromethorphan and reduce exposure to additional metabolites. Finally, saturation binding assays were performed to assess the manner in which dextromethorphan interacts at the s1 receptor. Our results revealed dextromethorphan displays antidepressant-like effects in the forced swim test that can be attenuated by pretreatment with s1 receptor antagonists, with BD1063 causing a shift to the right in the dextromethorphan dose response curve.
    [Show full text]
  • Antagonism of Histamine-Activated Adenylate Cyclase in Brain by D
    Proc. Natl. Acad. Sci. USA Vol.74, No. 12, pp. 5697-5701, December 1977 Medical Sciences Antagonism of histamine-activated adenylate cyclase in brain by D-lysergic acid diethylamide (histaminergic antagonists/adenosine 3':5'-cyclic monophosphate/H2-receptors/ergots/D-2-bromolysergic acid diethylamide) JACK PETER GREEN, CARL LYNN JOHNSON, HAREL WEINSTEIN, AND SAUL MAAYANI Department of Pharmacology, Mount Sinai School of Medicine of the City University of New York, 100th Street and Fifth Avenue, New York, New- York 10029 Communicated by Vincent P. Dole, August 19, 1977 ABSTRACT D-Lysergic acid diethylamide and D-2-bro- (ED50; amount necessary to produce half-maximal response) molysergic acid diethylamide are competitive antagonists of and antagonist affinities (pA2) were not altered. the histamine activation of adenylate cyclase [ATP pyrophos- Adenylate Cyclase Assay. The assay system has been de- phate-lyase (cyclizing); E.C. 4.6.1.11 in broken cell preparations in All additions of the hippocampus and cortex of guinea pig brain. The ade- scribed (8). All assays were performed triplicate. nylate cyclase is linked to the histamine H2-receptor. Both D- were made to the assay tubes on ice. They were then transferred lysergic acid diethylamide and D-2-bromolysergic acid dieth- to a 30° shaking incubator and preincubated for 5 min to allow ylamide show topological congruency with potent H2-antago- the enzymatic activity to reach a steady state and to eliminate nists. D-2-Bromolysergic acid diethylamide is 10 times more the influence of any lag periods in hormone activation. After potent as an H2-antagonist than cimetidine, which has been the the preincubation period, 25 of [a-32PJATP (1-2 gCi) were most potent H2-antagonist reported, and D-lysergic acid di- pl ethylamide is about equipotent to cimetidine.
    [Show full text]
  • Prohibited Substances List
    Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR). Neither the List nor the EADCM Regulations are in current usage. Both come into effect on 1 January 2010. The current list of FEI prohibited substances remains in effect until 31 December 2009 and can be found at Annex II Vet Regs (11th edition) Changes in this List : Shaded row means that either removed or allowed at certain limits only SUBSTANCE ACTIVITY Banned Substances 1 Acebutolol Beta blocker 2 Acefylline Bronchodilator 3 Acemetacin NSAID 4 Acenocoumarol Anticoagulant 5 Acetanilid Analgesic/anti-pyretic 6 Acetohexamide Pancreatic stimulant 7 Acetominophen (Paracetamol) Analgesic/anti-pyretic 8 Acetophenazine Antipsychotic 9 Acetylmorphine Narcotic 10 Adinazolam Anxiolytic 11 Adiphenine Anti-spasmodic 12 Adrafinil Stimulant 13 Adrenaline Stimulant 14 Adrenochrome Haemostatic 15 Alclofenac NSAID 16 Alcuronium Muscle relaxant 17 Aldosterone Hormone 18 Alfentanil Narcotic 19 Allopurinol Xanthine oxidase inhibitor (anti-hyperuricaemia) 20 Almotriptan 5 HT agonist (anti-migraine) 21 Alphadolone acetate Neurosteriod 22 Alphaprodine Opiod analgesic 23 Alpidem Anxiolytic 24 Alprazolam Anxiolytic 25 Alprenolol Beta blocker 26 Althesin IV anaesthetic 27 Althiazide Diuretic 28 Altrenogest (in males and gelidngs) Oestrus suppression 29 Alverine Antispasmodic 30 Amantadine Dopaminergic 31 Ambenonium Cholinesterase inhibition 32 Ambucetamide Antispasmodic 33 Amethocaine Local anaesthetic 34 Amfepramone Stimulant 35 Amfetaminil Stimulant 36 Amidephrine Vasoconstrictor 37 Amiloride Diuretic 1 Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR).
    [Show full text]
  • Rat Animal Models for Screening Medications to Treat Alcohol Use Disorders
    ACCEPTED MANUSCRIPT Selectively Bred Rats Page 1 of 75 Rat Animal Models for Screening Medications to Treat Alcohol Use Disorders Richard L. Bell*1, Sheketha R. Hauser1, Tiebing Liang2, Youssef Sari3, Antoinette Maldonado-Devincci4, and Zachary A. Rodd1 1Indiana University School of Medicine, Department of Psychiatry, Indianapolis, IN 46202, USA 2Indiana University School of Medicine, Department of Gastroenterology, Indianapolis, IN 46202, USA 3University of Toledo, Department of Pharmacology, Toledo, OH 43614, USA 4North Carolina A&T University, Department of Psychology, Greensboro, NC 27411, USA *Send correspondence to: Richard L. Bell, Ph.D.; Associate Professor; Department of Psychiatry; Indiana University School of Medicine; Neuroscience Research Building, NB300C; 320 West 15th Street; Indianapolis, IN 46202; e-mail: [email protected] MANUSCRIPT Key Words: alcohol use disorder; alcoholism; genetically predisposed; selectively bred; pharmacotherapy; family history positive; AA; HAD; P; msP; sP; UChB; WHP Chemical compounds studied in this article Ethanol (PubChem CID: 702); Acamprosate (PubChem CID: 71158); Baclofen (PubChem CID: 2284); Ceftriaxone (PubChem CID: 5479530); Fluoxetine (PubChem CID: 3386); Naltrexone (PubChem CID: 5360515); Prazosin (PubChem CID: 4893); Rolipram (PubChem CID: 5092); Topiramate (PubChem CID: 5284627); Varenicline (PubChem CID: 5310966) ACCEPTED _________________________________________________________________________________ This is the author's manuscript of the article published in final edited form as: Bell, R. L., Hauser, S. R., Liang, T., Sari, Y., Maldonado-Devincci, A., & Rodd, Z. A. (2017). Rat animal models for screening medications to treat alcohol use disorders. Neuropharmacology. https://doi.org/10.1016/j.neuropharm.2017.02.004 ACCEPTED MANUSCRIPT Selectively Bred Rats Page 2 of 75 The purpose of this review is to present animal research models that can be used to screen and/or repurpose medications for the treatment of alcohol abuse and dependence.
    [Show full text]
  • Medicines Classification Committee
    Medicines Classification Committee Meeting date 1 May 2017 58th Meeting Title Reclassification of Sedating Antihistamines Medsafe Pharmacovigilance Submitted by Paper type For decision Team Proposal for The Medicines Adverse Reactions Committee (MARC) recommended that the reclassification to committee consider reclassifying sedating antihistamines to prescription prescription medicines when used in children under 6 years of age for the treatment of medicine for some nausea and vomiting and travel sickness [exact wording to be determined by indications the committee]. Reason for The purpose of this document is to provide the committee with an overview submission of the information provided to the MARC about safety concerns associated with sedating antihistamines and reasons for recommendations. Associated March 2013 Children and Sedating Antihistamines Prescriber Update articles February 2010 Cough and cold medicines clarification – antihistamines Medsafe website Safety information: Use of cough and cold medicines in children – new advice Medicines for Alimemazine Diphenhydramine consideration Brompheniramine Doxylamine Chlorpheniramine Meclozine Cyclizine Promethazine Dexchlorpheniramine New Zealand Some oral sedating antihistamines available without exposure to a prescription (pharmacist-only and pharmacy only), sedating therefore usage data is not easily available. antihistamines Table of Contents 1.0 PURPOSE ......................................................................................................................................
    [Show full text]